4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Glaucoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 250 ongoing clinical trials involving Glaucoma
Of the 250 trials,113 trials are in Phase III
Furthermore, 61 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Glaucoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Glaucoma, an ophthalmology indication. The highest number of ongoing clinical trials involving Glaucoma is in the Asia-Pacific region. Europe and North America are among some of the other prominent regions involved in Glaucoma-related drug trials.

Santen Pharmaceutical Co Ltd: The leading ongoing Glaucoma related clinical trials sponsor

Santen Pharmaceutical Co Ltd, the Japan-based pharmaceutical and healthcare company, is the top sponsor for Glaucoma-related ongoing clinical trials.

Allergan Ltd, Sun Yat-sen University, Kowa Co Ltd, and Intratus Incare a few other notable sponsors involving Glaucoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Glaucoma

Aflibercept (Eylea), Bimatoprost (Lumigan/Lumivis/Lumopta), Brimonidine tartrate (Alphagan, Alphagan P, Enidin P), and Dorzolamide hydrochloride and timolol maleate (Cosopt, Cosopt Mini, Dormolol, Cosopt PF) are among the key marketeddrugs involving Glaucoma.     

Aflibercept (Eylea), a Placenta Growth Factor Inhibitor, and Vascular Endothelial Growth Factor AInhibitor drug, is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Eylea is indicated for the treatment of Glaucoma and several other indications including Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema, Myopia, Diabetic Macular Edema, Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy (NPDR), Wet (Neovascular / Exudative) Macular Degeneration. The drug is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Regeneron Pharmaceuticals Inc, and Bayer AG. Aflibercept was first approved in 2011 and is formulated as an iso-osmotic injection solution for intravitreal route of administration.

Bimatoprost (Lumigan/Lumivis/Lumopta), a Prostaglandin F2 Alpha Receptor (Prostanoid FP Receptor or PTGFR) Agonist drug, is a synthetic prostaglandin analog, acts as a potent ocular hypotensive agent. Bimatoprost is indicated for reducing the elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Lumigan is marketed globally including the US, the UK, Australia, France, Germany, and Japan by several prominent pharma giants including AbbVie Inc, Allergan Ltd, and Shionogi & Co Ltd. Lumigan was first approved in 2001 and is formulated as drops, solution for ophthalmic route of administration.